L-Carnitine is the amino acid derivative that is one of the most important regulators of the fatty acid entry into the mitochondria — it is synthesised in the liver and the kidneys from the lysine and the methionine, and it is the essential cofactor for the carnitine shuttle system (CPT1, CACT, CPT2) that transports the long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. The L-carnitine is the only known physiological compound that can transport the long-chain fatty acids (palmitate, oleate, stearate) into the mitochondrial matrix, because the inner mitochondrial membrane is impermeable to the CoA esters, and the fatty acyl-CoA must be converted to the fatty acyl-carnitine (by the CPT1) before they can cross the membrane (through the CACT, the carnitine-acylcarnitine translocase) and be converted back to the fatty acyl-CoA (by the CPT2) in the matrix. Without adequate L-carnitine and fatty acid transport, the mitochondria cannot oxidise the fatty acids efficiently, the energy production is impaired, and the metabolic syndrome, the cardiomyopathy, and the neurodegeneration develop — the hallmark of the L-carnitine deficiency and of the disorders of the fatty acid oxidation that are associated with the primary carnitine deficiency, the secondary carnitine deficiency (due to the valproic acid, the pivampicillin, the isoniazid), and the disorders of the fatty acid oxidation (MCAD deficiency, LCAD deficiency, VLCAD deficiency). The typical dietary L-carnitine intake from the red meat, the poultry, the fish, and the dairy is approximately 20-200mg daily, and the endogenous synthesis (from the lysine and the methionine in the liver and the kidneys) is the primary source of the L-carnitine in the body — making it a conditionally essential amino acid that may become deficient in people with the liver disease, the kidney disease, the vegan diet, or the increased energy demands (exercise, pregnancy, catabolism).
L-Carnitine and the Metabolic Syndrome
L-Carnitine supports the metabolic health primarily through its role as the essential cofactor for the fatty acid oxidation and for the glucose metabolism — the L-carnitine enables the mitochondria to oxidise the fatty acids for energy, and it thereby prevents the accumulation of the fatty acids in the cytosol, reduces the insulin resistance, improves the glycemic control, and reduces the triglycerides and the hepatic fat content. The L-carnitine also improves the insulin sensitivity by reducing the diacylglycerol and the ceramide accumulation in the skeletal muscle (which are the primary drivers of the insulin resistance), and it thereby reduces the risk of the type 2 diabetes and the metabolic syndrome. The L-carnitine also has a secondary effect on the glucose metabolism through its activation of the AMPK (which is the master regulator of the glucose uptake and of the mitochondrial biogenesis) and through its inhibition of the acetyl-CoA carboxylase (which is the rate-limiting enzyme of the fatty acid synthesis). This multi-target mechanism of action (fatty acid oxidation promotion, insulin sensitivity improvement, AMPK activation, ACC inhibition) makes the L-carnitine one of the most effective and most comprehensive metabolic health nutrients known — and it explains why the L-carnitine supplementation has been shown to improve the metabolic parameters in people with the metabolic syndrome, the type 2 diabetes, and the non-alcoholic fatty liver disease.
The clinical importance of the L-carnitine for the metabolic health is underscored by the observation that the L-carnitine supplementation improves the metabolic parameters and reduces the markers of the metabolic syndrome in multiple large meta-analyses. A meta-analysis of 30 RCTs in over 2000 patients with the metabolic syndrome found that the L-carnitine supplementation at 2-4g daily significantly reduced the fasting glucose (by 5-10%), reduced the HbA1c (by 0.5-1%), reduced the triglycerides (by 10-15%), and improved the insulin sensitivity (by 10-15%) — demonstrating the potent and clinically meaningful metabolic-protective effect of the L-carnitine in humans with the metabolic dysfunction.
Practical Application
For general L-carnitine supplementation for the metabolic health and for the fatty acid oxidation support, the evidence-based approach is to supplement with 2-4g of L-carnitine daily (as the L-carnitine tartrate or the acetyl-L-carnitine, taken in divided doses with the meals). The L-carnitine should be taken with the alpha-lipoic acid (which is a potent insulin sensitiser and which works synergistically with the L-carnitine for the improvement of the metabolic function and for the reduction of the insulin resistance — the combination of the L-carnitine and the alpha-lipoic acid is one of the most effective and most evidence-based combinations for the metabolic syndrome and for the type 2 diabetes). The L-carnitine is generally well-tolerated with no significant adverse effects at the doses that are used for the metabolic support (up to 6g daily), though the very high doses may cause the mild gastrointestinal discomfort or the fishy body odour (due to the trimethylamine production by the gut bacteria). For comprehensive metabolic health and fatty acid oxidation support, L-carnitine pairs well with the alpha-lipoic acid (which is a potent insulin sensitiser that works synergistically with the L-carnitine for the metabolic health and for the improvement of the insulin sensitivity — the combination of the L-carnitine and the alpha-lipoic acid is one of the most effective combinations for the metabolic syndrome and for the reduction of the cardiovascular risk), with the chromium (which is an essential mineral for the insulin function and which works synergistically with the L-carnitine for the improvement of the glycemic control — the combination of the L-carnitine and the chromium is one of the most effective combinations for the reduction of the fasting glucose and for the improvement of the HbA1c in people with the type 2 diabetes), with the omega-3 fatty acids (which are the primary substrate for the fatty acid oxidation and which work synergistically with the L-carnitine for the metabolic health and for the reduction of the triglycerides — the combination of the L-carnitine and the omega-3 fatty acids is one of the most effective combinations for the reduction of the cardiovascular risk and for the improvement of the lipid profile), and with the vitamin B5 (which is the precursor of the CoA and which works synergistically with the L-carnitine for the energy metabolism and for the fatty acid oxidation — the combination of the L-carnitine and the vitamin B5 is one of the most effective combinations for the optimisation of the fatty acid metabolism and for the prevention of the metabolic syndrome).
Leave a Reply